Platelets play a critical role in the pathophysiology of reperfusion, sepsis, and cardiovascular diseases. In a multiple step process, they adhere to activated endothelium and release proinflammatory cytokines thereby promoting the inflammatory process. Glycoprotein VI (GPVI) is the major collagen receptor on the platelet surface and triggers platelet activation and primary hemostasis. Activation of GPVI leads to stable platelet adhesion and degranulation of platelet granules. However, GPVI is critically involved in platelet adhesion to activated endothelium without exposure of subendothelial matrix. Earlier studies show that the soluble GPVI-Fc binds to collagen and protects mice from atherosclerosis and decreases neointima proliferation after arterial injury. Here, we show for the first time that recombinant GPVI-Fc binds to activated endothelium mainly via vitronectin and prevents platelet/endothelial interaction. Administration of GPVI-Fc reduced infarct size and preserved cardiac function in a mouse model of myocardial infarction. This process was associated with reduced GPVI-induced platelet degranulation and release of proinflammatory cytokines in vitro and in vivo. Taken together, administration of GPVI-Fc offers a novel strategy to control plateletmediated inflammation and to preserve myocardial function following myocardial infarction. glycoprotein VI; platelet; endothelium; myocardial infarction; reperfusion PLATELET ADHESION TO ENDOTHELIUM plays a crucial role in the pathophysiology of reperfusion, sepsis, and cardiovascular diseases (21, 45, 46) . Platelet activation and interaction with endothelium contribute to microcirculatory disturbances (33) and multiorgan dysfunction (18, 19) . Endothelial cell dysfunction allows platelet adhesion even without exposure of extracellular matrix (24, 32, 46) . Similar to the recruitment of leukocytes (52), the adhesion of platelets to the endothelial surface is a multistep process, in which platelets are tethered to the vascular wall, followed by firm adhesion and subsequent release of proinflammatory cytokines/chemokines (20). Whereas the adhesion receptors involved in platelet adhesion to the subendothelial matrix have been well defined (13, 24, 28, 32, 41, 45) , the molecular requirements that regulate the interaction between platelets and the intact vascular endothelium and their pathophysiological consequences are incompletely understood.
PLATELET ADHESION TO ENDOTHELIUM plays a crucial role in the pathophysiology of reperfusion, sepsis, and cardiovascular diseases (21, 45, 46) . Platelet activation and interaction with endothelium contribute to microcirculatory disturbances (33) and multiorgan dysfunction (18, 19) . Endothelial cell dysfunction allows platelet adhesion even without exposure of extracellular matrix (24, 32, 46) . Similar to the recruitment of leukocytes (52) , the adhesion of platelets to the endothelial surface is a multistep process, in which platelets are tethered to the vascular wall, followed by firm adhesion and subsequent release of proinflammatory cytokines/chemokines (20) . Whereas the adhesion receptors involved in platelet adhesion to the subendothelial matrix have been well defined (13, 24, 28, 32, 41, 45) , the molecular requirements that regulate the interaction between platelets and the intact vascular endothelium and their pathophysiological consequences are incompletely understood.
At sites of arterial injury the glycoprotein VI (GPVI)-collagen interaction is a major trigger of platelet activation and primary hemostasis. GPVI is the major collagen receptor on the platelet surface and represents an immunoreceptor tyrosinebased activation motif (ITAM)-coupled receptor (14, 41) . GPVI binding to collagen induces an intracellular signaling cascade that involves serial activation of Src and Syk family tyrosine kinases leading to the activation of effector proteins such as phospholipase (PL)C␥2, phosphoinositide-3-kinase, and small G proteins (42, 54, 57) . Activated PLC␥2 triggers Ca 2ϩ mobilization and protein kinase C (PKC) activation that results in the activation of ␤ 1 -and ␤ 3 -integrins, a critical step for stable platelet adhesion to extracellular matrix proteins (41) . Furthermore, GPVI activation leads to degranulation of platelet alpha and dense granules that contain various proteins such as growth factors, thrombogenic proteins, and chemokines that contribute significantly to the inflammatory response around the microenvironment of activated platelets (8, 15, 27, 53) .
Surface expression of GPVI is enhanced in patients with acute coronary syndrome (3, 4) and is associated with poor prognosis (2) . Recently, it has been shown that GPVI is critically involved in platelet adhesion to diseased endothelium of carotid arteries in ApoE Ϫ/Ϫ mice (32) . Previously, we (34, 56) have generated a dimeric soluble form of the human platelet glycoprotein GPVI that was fused to the human Fc fragment and binds with high affinity to collagen. GPVI-Fc protects against atherosclerosis in both rabbits and ApoE Ϫ/Ϫ mice (10, 49) and reduces neointima proliferation after arterial injury in mice (48) .
In the present study, we characterized binding of GPVI-Fc to activated endothelium and investigated the effect of this molecule on platelet-mediated inflammation and on myocardial function after transient myocardial ischemia in mice.
MATERIALS AND METHODS
Reagents. Human von Willebrand Factor (vWF) from Calbiochem (Bad Soden, Germany) and bovine collagen I from BD Biosciences (Heidelberg, Germany) were used. TNF-␣ and IFN-␥ were purchased from PeproTech (Hamburg, Germany). Mouse anti-human P-selectin FITC-conjugated antibody or isotype IgG1 control antibody from Beckman Coulter (Krefeld, Germany) were used. Monoclonal antibody (mAb) 4C9 was generated against soluble human GPVI in rat as described elsewhere (11) . Human anti-IgG, Fc FITC-conjugated antibody from Dianova (Hamburg, Germany) was used.
The recombinant fusion protein GPVI-Fc. The dimeric soluble GPVI-Fc molecule (Revacept) is a fusion protein consisting of the extracellular part of the human platelet collagen receptor GPVI and the Fc domain of human IgG1 (34, 56) . The recombinant protein GPVI-Fc was produced and purified as described previously (34, 56) . A corresponding IgG1-Fc (termed Fc) without the GPVI domain was designed as control protein.
Cell culture. Primary human umbilical vein endothelial cells (HUVECs; PromoCell) were grown up in 24-well culture plates (Nunc) according to manufacturer's instructions and as described previously (6) . Native Chinese hamster ovary (CHO) cells and CHO cells with stable GPVI expression on the cell surface were cultured as described (34) in DMEM medium (GIBCO) containing 10% FCS, 1% penicillin/streptomycin, 1% L-glutamine, and 1% MEM.
Binding of GPVI-Fc to endothelial cells. Confluent monolayers of HUVECs were stimulated with TNF-␣ (50 ng/ml) and INF-␥ (20 ng/ml) for 16 h, followed by incubation with 10 g/ml GPVI-Fc or Fc, respectively, to test GPVI binding. After detachment by trypsination, cells were analyzed for GPVI-Fc binding after being stained with FITC-conjugated anti-IgG antibody as indicated followed by flow cytometry as described previously (21) .
GPVI binding to immobilized ligands. For assessment of GPVI-Fc binding to immobilized ligands, 96-well ELISA plates (Immulon2 HB; Dynx Technologies, Chantilly, VA) were coated overnight at 4°C with 1 g collagen (type I bovine), 2 g native and multimeric vitronectin (Vn) in concentrations as indicated, or 2 g vWF in 100 l coating buffer (1.59 g/l Na 2CO3, 2.93 g/l NaHCO3, and 0.2 g/l NaN 3 pH 9.6; 34). With the use of the same experimental protocol, the effects of different mAbs, i.e., a rat monoclonal blocking anti-GPVI antibody 5C4 (10 g/ml; Ref. 34 ) and a mAb 16A7 against Vn (10 g/ml; provided by Dr. P. Declerk, University of Leuven), or excess of soluble native or multimeric Vn (50 -100 g/ml) on GPVI-Fc binding to immobilized ligands were analyzed.
Vn binding to immobilized GPVI-Fc. Binding of native and multimeric Vn to immobilized GPVI-Fc was determined by ELISA technique as described previously (26, 34) . To test the specificity of the binding, the mAb to Vn, mAb 153, and mAb M4 were used.
Flow chamber experiments with isolated platelets and GPVIexpressing CHO cells. Human platelets were isolated from acidcitrate-dextrose-anticoagulated whole blood as described (21, 39) . Washed platelets were resuspended in Tyrode-HEPES buffer (2.5 mmol/l HEPES, 150 mmol/l NaCl, 12 mmol/l NaHCO 3, 2.5 mmol/l KCl, 1 mmol/l MgCl 2, 5.5 mmol/l D-glucose, and 1 mg/ml BSA, pH 7.4) to obtain a platelet count of 2 ϫ 10 8 cells/ml. Experiments were performed as described elsewhere (34, 47) . Coverslips were covered with confluent monolayers of primary HUVECs or ECV-304 and partially activated with TNF-␣ (50 ng/ml) and INF-␥ (20 ng/ml) for 16 h. Thereafter, the cells were pretreated with GPVI-Fc (100 g/ml; 34) or with Fc control protein (33 g/ml) for 60 min. In experiments with immobilized ligands, glass coverslips were coated with collagen, vWF, or Vn. Adhesion of isolated platelets, native CHO-or GPVI-expressing CHO cells, respectively, was monitored for 10 min at a wall shear rate of 2,000 s Ϫ1 after preincubation of immobilized proteins with GPVI-Fc or control Fc in a parallel plate flow chamber (34, 47) . In addition, the effect of 1 mM EDTA on GPVI-dependent platelet adhesion to immobilized ligands was evaluated.
Adhesion-dependent activation and transforming growth factor (TGF)-␤1 release of platelets in vitro. A 96-well plate was coated with 10 g/ml 4C9 (a platelet-activating rat mAb against human GPVI) or 10 g/ml collagen I in PBS over night at 4°C. Wells were washed with PBS, blocked with BSA, and incubated with GPVI-Fc (200 g/ml) or control Fc (equimolar). BSA was used as control coating and showed basal platelet activation and cytokine release. Human platelets were isolated from acid-citrate-dextrose-anticoagulated whole blood as described previously (21, 39) . Then, 1 ϫ 10 6 prepared platelets were added to the coated wells and incubated for 1 h. After incubation, one part of the cells was stained for 30 min with mouse anti-human P-selectin FITC-conjugated antibody or FITCconjugated isotype IgG1 control antibody and analyzed by flow cytometry to assess platelet activation.
From the other part of the wells, we collected the supernatant after a 1-h incubation and lysed the platelets with 50 l lysis buffer for 20 min at 4°C. TGF-␤1 concentration in supernatant and cell lysate was measured using human TGF-␤1 ELISA according to the manufacturer's protocol.
Flow cytometry. Flow cytometry analysis was performed as described previously (32, 42) . Briefly, analysis of platelet activation was performed using a fluorophore-labeled antibody for P-selectin expression (Beckman Coulter). 4C9 (a platelet activating antibody against GPVI) or collagen was pretreated with GPVI-Fc (200 g/ml) or control Fc, respectively, and incubated with platelets for 1 h. BSA was used as control. Reaction was stopped by the addition of PBS, and samples were analyzed on a FACS-Calibur flow cytometer (BD Biosciences).
Animals. Specific pathogen-free wild-type C57BL/6J mice were obtained from Charles River (Sulzfeld, Germany). All animal experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996), guidelines for the use of living animals in scientific studies, and the German law for the protection of animals. The animal studies were approved by the district government of Tübingen.
Myocardial ischemia and reperfusion in mice. To determine the effect of GPVI-Fc administration on myocardial infarct size, transient ligation of the left anterior descending artery (LAD) for 30 min was performed in male C57BL/6J mice in vivo. Mice were randomly assigned to receive either GPVI-Fc (10 g/g body wt; n ϭ 5) or Fc control (equimolar; n ϭ 5) by intravenous injection 10 min before reperfusion. Mice were killed 24 h after ischemia, blood was collected, and their hearts were removed. Infarct size and area at risk (AaR) were assessed by triphenyltetrazolium chloride and 1% Evans blue staining, as described in detail elsewhere (7) . From additional animals, hearts were removed and frozen to determine cytokine mRNA levels. A further GPVI-Fc group (10 g/g body wt) and Fc control group were treated twice; first injection was intravenously during ischemia and second administration intraperitoneally 72 h later. Twenty-eight days after ischemia and reperfusion (I/R) echocardiography was performed and infarct size was assessed (50) . In a more clinical approach, additional mice received GPVI-Fc and Fc, respectively, 6 h after I/R and were killed 24 h later.
Hematoxylin and eosin and immunostaining. Paraffin-embedded cardiac sections 1 day after myocardial infarction were stained with hematoxylin and eosin according to a standard protocol. Immunostaining of infarcted cardiac sections was performed with a streptavidin-biotin-immunoperoxidase method (StreptABComplex/HRP, liquid diaminobenzidine, Substrate-Chromogen; Dako, Heverlee, Belgium). As primary mAbs, anti-Mac-3 (BD Biosciences, San Jose, CA), anti-CD3 (Neomarkers, Fremont, CA), anti-polymorphonuclear (NIMP-R14; GeneTex, Irvine, CA), and isotype control mAb were used. Corresponding secondary antibodies (Dako) were used according to standard protocols. The percentage of Mac-3-, polymorphonuclear-, and CD3-positive cells was counted from six random areas in the infarcted myocardium of each heart sample (n ϭ 3) in a blinded manner.
Quantitative PCR for cytokine mRNA levels. One day after myocardial ischemia mice treated with GPVI-Fc or control Fc were killed and their hearts were removed. mRNA were isolated from the left ventricle (LV) to determine the expression level of the cytokines TNF-␣, TGF-␤1, monocyte chemoattractant protein-1 (MCP1), IL-1␣, IL-1␤, IL-6, and IL-10. After reverse transcription, quantitative PCR amplification was performed using special generated oligonucleotide primers (Table 1) . Expression was normalized to GAPDH mRNA expression levels as an internal control.
ELISA. Serum samples from mice treated with GPVI-Fc or control Fc were analyzed. Serum concentration of IL-1␣ and TGF-␤1 were quantified by ELISA according to the manufacturer's instructions (R&D Systems, Minneapolis, MN).
Statistics. All experiments were carried out at least three times. Results are depicted throughout as means Ϯ SE. Statistical analysis was performed using PRISM (GraphPad Software, La Jolla, CA) and Student's t-test statistics. Statistical significance was set at P Ͻ 0.05.
RESULTS
The dimeric human collagen receptor GPVI-Fc binds to activated endothelium in vitro. Platelet GPVI has been shown to mediate platelet adhesion to endothelium in the absence of vascular lesions (10) . To further evaluate the mechanisms of GPVI-mediated platelet adhesion to endothelium, binding of a dimeric soluble GPVI-receptor (GPVI-Fc; 34) or control Fc to TNF-␣/INF-␥-activated HUVECs was evaluated by immunofluorescence and FACS analysis (Fig. 1A) . Binding of GPVI-Fc to activated endothelial cells was significantly enhanced compared with Fc control (P Ͻ 0.001). To test whether GPVI-Fc regulates platelet adhesion to TNF-␣/INF-␥-activated endothelial cells, platelets were perfused over an activated HUVEC monolayer for 10 min. We observed an ϳ50% reduction of platelet adhesion to endothelial cells compared with Fc control-treated or untreated HUVECs (P Ͻ 0.01) in the presence of GPVI-Fc (Fig. 1B) . Furthermore, platelets were perfused over activated and nonactivated ECVs and showed a significantly reduced platelet adhesion if the activated ECVs were preincubated with GPVI-Fc compared with Fc control or untreated ECVs (P Ͻ 0.001). Nonactivated ECVs showed a marginal interaction with platelets (Fig. 1C) .
Immobilized Vn is a ligand for GPVI-Fc. To identify specific ligands of GPVI-Fc, we directly assessed binding of recombinant GPVI-Fc to several immobilized adhesion proteins (vWF, Vn). Dimeric GPVI-Fc specifically bound to immobilized Vn in a concentration-dependent manner ( Fig. 2A) . In contrast, virtually no GPVI-Fc binding to immobilized vWF was evident. Binding of soluble GPVI-Fc to Vn was substantially inhibited in the presence of a Fab fragment of the blocking anti-GPVI mAb 5C4 (34) (Fig. 2B) . Further, GPVI-Fc binding to immobilized collagen I was unaffected by the excess of soluble native (Vn nat ) or multimeric (Vn mult ) Vn or anti-Vn mAb 16A7 determined by ELISA (Fig. 2C) . In contrast, specific binding of soluble GPVI-Fc to immobilized Vn nat or Vn mult was substantially reduced by the blocking anti-Vn mAb 16A7 or by soluble Vn, respectively (Fig. 2D) . Next, we determined binding of Vn nat and Vn mult to immobilized GPVIFc. Both forms of Vn bound specifically to GPVI-Fc in a concentration-dependent manner (Fig. 2E) . The binding was Table 1 . Sequences for oligonucleotide primers
GCTATGCTGCCTGCTCTTACTGAC CAGGGGAGAAATCGATGACAGCG TGF-␤1, transforming growth factor-␤1; MCP1, monocyte chemoattractant protein-1. inhibited by an anti-Vn mAb153 that specifically recognizes the amino-terminal site of Vn but not by mAb M4 that detects the collagen-binding domain of Vn (data not shown). To test whether GPVI-Fc binds to adhesion receptors, we incubated CHO cells stably transfected with ␣ v ␤ 3 , P-selectin, or intercellular adhesion molecule-1 with soluble GPVI-FC or control Fc, respectively. No specific binding of GPVI-Fc to these cells was found (data not shown). Adhesion of isolated platelets on immobilized purified human Vn, vWF, or collagen under flow conditions was monitored after preincubation with GPVI-Fc or control Fc (20 g, each) in a parallel plate flow chamber. Firm platelet adhesion to all ligands tested occurred within 5 min, and this was not significantly altered when coverslips had been preincubated with control Fc. In contrast, preincubation with GPVI-Fc reduced platelet adhesion to collagen and Vn by ϳ50%, whereas adhesion to vWF was hardly affected by the treatment (Fig. 2F) . Furthermore, CHO cells stably transfected with human GPVI showed substantially enhanced adhesion to immobilized Vn and collagen (Fig. 2G ) compared with nontransfected cells. The recombinant fusion protein GPVI-Fc reduces infarct size and preserves LV function in mice. We used a mouse model of myocardial ischemia to assess the effects of GPVI-Fc administration on myocardial function in vivo. In this model, myocardial infarction was induced by LAD ligation for 30 min (7). C57BL/6J mice were treated with GPVI-Fc or control Fc (Fig. 3A) infarct size after transient LAD ligation compared with control Fc-treated mice by ϳ47% 1 day after I/R ( Fig. 3B ; P Ͻ 0.05).
A B
Total cell number and cell quality were analyzed 1 day after myocardial infarction using immunohistochemical staining (50). We did not find differences of total cell number, amount of CD3-positive cells, macrophages and polymorphonuclear cells in areas of myocardial ischemia between GPVI-Fc and control Fc-treated mice (Fig. 3, C-F) .
In a more clinical setting, the mice received GPVI-Fc and control Fc 6 h after myocardial I/R. The hearts were removed 24 h after myocardial infarction, and infarction size was analyzed. Again, we found a smaller infarct size in the GPVI-Fc-treated group resulting in an ϳ89% reduced infarct size (2.7 Ϯ 1.5% I/AaR vs. 25.7 Ϯ 10.1% I/AaR; n ϭ 5; P Ͻ 0.05; Fig. 3B) .
To analyze the impact of GPVI-Fc treatment on heart function, we performed a two-time administration of GPVI-Fc or control Fc (Fig. 3G) , at which the first injection was carried out at the end of the ischemia. We found reduced infarct areas 28 days after reperfusion in GPVI-Fc-treated mice compared with control Fc-treated mice by trend (Fig. 3H , top right, GPVI-Fc 39.2 Ϯ 7.7% I/AaR compared with Fc 54.1 Ϯ 15.4% I/AaR; P ϭ 0.11). Nevertheless, reduction of infarct size was functionally relevant because echocardiography 28 days after LAD ligation showed significantly improved cardiac LV function by ϳ37% in mice treated with GPVI-Fc compared with control Fc-treated mice (Fig. 3H , bottom, GPVI-Fc 34.0 Ϯ 1.9% fractional area change vs. Fc 46.7 Ϯ 1.5% fractional area change; P Ͻ 0.001).
GPVI-Fc reduces inflammatory response in infarcted myocardium in mice. The expression of different cytokines/chemokines in the LV 1 day after I/R was determined using quantitative RT-PCR. TNF-␣, TGF-␤1, monocyte chemoattractant protein-1, IL-6, IL-1␣, and IL-1␤ were significantly increased in the infarcted LV 24 h after I/R compared with intact, untreated LV (Fig. 4A) . In contrast, the expression of IL-10 was unaffected by LAD ligation. However, the expression levels of all the before increased cytokines/chemokines were significantly reduced in the GPVI-Fc-treated group compared with Fc control (Fig. 4A) . These cytokines nearly returned to baseline levels following treatment with GPVI-Fc (Fig. 4A) . Serum concentrations of TGF-␤1 and IL-1␣ were determined by ELISA. Twenty-four hours after I/R both cytokines showed equal serum levels in the GPVI-Fc-treated group and the Fc control group (Fig. 4B) . Taken together, these data demonstrated that soluble GPVI-Fc modulated the inflammatory profile by reducing inflammatory response specifically in the heart after transient ischemia.
GPVI-Fc inhibits release of platelet-derived cytokines in vitro. The administration of GPVI-Fc reduced the inflammatory response (e.g., release of TGF-␤1) after myocardial infarction as shown above (Fig. 4) . Therefore, we tested if GPVI-Fc is able to modulate the release of platelet-derived cytokines in vitro. Isolated human platelets were incubated on 4C9 (11) (a platelet activating antibody against GPVI) or collagen pretreated with GPVI-Fc (200 g/ml) or control Fc. After incubation, P-selectin expression was determined by flow cytometry to assess platelet activation (Fig. 5, A and D) . Moreover, the concentration of TGF-␤1 was measured in platelet lysates as well as in the supernatant of GPVI-stimulated platelets using a specific ELISA to determine cytokine release (Fig. 5, B, C, E, and F) . GPVI-Fc decreased 4C9-activated P-selectin surface expression on platelets compared with Fc control (Fig. 5A, 4C9 ϩ GPVI-Fc: mean fluorescence intensity ϭ 11.9 Ϯ 1.2 compared with Fc: mean fluorescence intensity ϭ 32.4 Ϯ 2.7; P Ͻ 0.01). Similarly, platelet release of 4C9-induced TGF-␤1 was attenuated in the presence GPVI-Fc compared with Fc control group (Fig. 5B) . In parallel, the TGF-␤1 concentration in platelet lysates was enhanced after incubation with GPVI-Fc compared with controls (Fig. 5C , 4C9 ϩ GPVI-Fc: 2982 Ϯ 433 pg/ml compared with 4C9 ϩ Fc: 2,089 Ϯ 82 pg/ml; P Ͻ 0.05). Further, incubation of platelets on a collagen matrix in the presence of GPVI-Fc showed similar effects as coating with 4C9 and GPVI-Fc (Fig. 5, D-F) . Taken together, our data demonstrate that treatment of platelets with GPVI-Fc prevented GPVI-dependent platelet degranulation of P-selectin and TGF-␤1 (Fig. 5) , implying an important impact on platelet-mediated inflammatory response.
DISCUSSION
The major findings of this study are the following ones: 1) the recombinant fusion protein GPVI-Fc binds to activated endothelial cells and inhibits platelet/endothelium adhesion.
2) GPVI-Fc binds to immobilized Vn, which is associated on Taken together, our findings indicate that the dimeric soluble fusion protein GPVI-Fc binds to activated endothelium, reduces platelet/endothelium adhesion, and attenuates plateletmediated inflammatory responses that contribute to myocardial repair mechanisms following transient ischemia. Administration of GPVI-Fc in acute myocardial infarction may be a novel strategy to limit inflammation of the diseased myocardium.
GPVI has been established as the central platelet collagen receptor that is essential for platelet adhesion and aggregation on immobilized collagen in vitro and in vivo (32, 41) . Previously, we (9, 34) have designed and generated a dimeric soluble fusion protein GPVI-Fc that potently inhibits arterial thrombosis in vitro and in vivo. A recent study (49) of our group showed that the binding of platelets to collagen and human atheromatous plaque is mediated by GPVI in vitro. Further, we showed that GPVI mediates platelet adhesion to endothelium early in the process of atherosclerosis and that prolonged administration of soluble GPVI-Fc reduces atheroprogression in mice and rabbits (10) .
Previously, it was recognized that platelet adhesion and activation on endothelium is enhanced in patients with acute myocardial infarction (21, 22) and is associated with myocardial inflammation (29, 40) .
To test whether binding of platelets to endothelium is GPVI mediated, we used a recombinant soluble dimeric GPVI-Fc (34, 38) . Incubation of HUVECs and ECV-304 cells with GPVI-Fc resulted in a reduction of platelet adhesion, suggesting that activated endothelium exposes binding sites for GPVI. Further, we show that GPVI-Fc bound directly to endothelial cells. Thus these data provide evidence that GPVI recognizes a binding partner on endothelial cells that mediates platelet adhesion to endothelium. Activated endothelial cells express a variety of adhesion receptors (e.g., ␤ 3 -integrin, P-selectin, and intercellular adhesion molecule-1; Refs. 5, 12, 16, 17, 23, 31) and bind adhesion proteins such as vWF (1) or Vn (59) that all have been shown to play a role in platelet/endothelium adhesion. Since these adhesion molecules are presented in substantial amounts on the luminal aspect of endothelial cells, they are potential candidates for endothelial GPVI ligands. To identify specific ligands of GPVI, we directly assessed binding of recombinant GPVI-Fc to several immobilized adhesion proteins (vWF, Vn). Here, we show that GPVI is not an exclusive receptor for immobilized collagen but also binds specifically to other adhesion molecules such as Vn. Further, binding of Vn mult to immobilized GPVI was inhibited by an anti-Vn mAb153 that specifically recognizes the amino-terminal site of Vn but not by mAb M4 that recognizes the collagen-binding domain of Vn (data not shown). This indicates that interaction of Vn with GPVI is primarily mediated by the amino-terminal domain of Vn.
Moreover, we found that GPVI-Fc regulates platelet adhesion to activated endothelial cells that show enhanced expression of surface-associated Vn. The effect of soluble GPVI-Fc on platelet adhesion to Vn was not dependent on divalent cations, because a similar extent of inhibition was found in the presence of EDTA. Thus inhibition of platelet adhesion to immobilized Vn through soluble GPVI-Fc is independent of integrin receptors.
Furthermore, CHO cells stably transfected with human GPVI (34) showed increased adhesion to immobilized Vn. This finding demonstrates that GPVI alone is sufficient to mediate cellular adhesion on Vn and establishes a novel role of GPVI for platelet physiology.
Activation of endothelial cells induces apical binding of Vn both on cultured endothelium in vitro (26, 51, 59) and in atherogenic diabetic mice in vivo (25) . Earlier, we demonstrated by intravital fluorescence microscopy that platelets adhere to the intact and activated endothelium of the carotid artery in ApoE Ϫ/Ϫ mice before lesion formation (30) . In ApoE Ϫ/Ϫ mice that were on cholesterol-enriched diet for 6 wk, significant platelet adhesion occurs at lesion-prone sites, but no lesion formation was detectable by histochemistry (30) . . GPVI mediates release of platelet-derived cytokines in vitro. 4C9 (a platelet activating antibody against GPVI) or collagen was pretreated with GPVI-Fc (200 g/ml) or control Fc, respectively, and incubated with human platelets for 1 h. BSA was used as control and showed basal P-selectin expression and cytokine release. A: expression of P-selectin by flow cytometry showed reduced activation of platelets on 4C9 ϩ GPVI-Fc-coated surfaces compared with 4C9 ϩ control Fc-coated surfaces (**P Ͻ 0.01). B: TGF-␤1 concentration was measured by ELISA. TGF-␤1 concentration in supernatant was reduced on 4C9 ϩ GPVI-Fc-coated surfaces compared with 4C9 ϩ control Fc-coated surfaces (P ϭ 0.160). C: TGF-␤1 concentration in platelet lysates was increased on 4C9 ϩ GPVI-Fc-coated surfaces compared with 4C9 ϩ control Fc-coated surfaces (*P Ͻ 0.05). D: FACS analysis of P-selectin exposure showed reduced activation of platelets on collagen ϩ GPVI-Fc-coated surfaces compared with collagen ϩ control Fc-coated surfaces (*P Ͻ 0.05). E: TGF-␤1 concentration in supernatant was reduced on collagen ϩ GPVI-Fc-coated surfaces compared with collagen ϩ control Fc-coated surfaces (*P Ͻ 0.05). F: TGF-␤1 concentration in platelet lysates was increased on collagen ϩ GPVI-Fc-coated surfaces compared with collagen ϩ control Fc-coated surfaces (**P Ͻ 0.01).
From recent studies (10, 49), we knew that prolonged administration of soluble GPVI-Fc attenuates atheroprogression in ApoE Ϫ/Ϫ mice. Our present data strongly suggest that the interaction of GPVI with Vn presented on activated endothelium is of biological relevance and mediates platelet adhesion in vivo.
Next, we asked whether the observed reduction of plateletendothelium adhesion during reperfusion in mice has functional consequences for tissue ischemia of the myocardium when pretreated with GPVI-Fc. We found that administration of soluble GPVI-Fc before and during reperfusion reduces myocardial ischemia in mice, indicating that platelet-endothelial interaction plays a critical role for remodeling of ischemic myocardium.
In the in vivo models described herein, platelet interaction to the vessel wall was dependent on GPVI-Fc in the absence of vascular lesions or defects of the endothelial monolayer. I/R of myocardium was induced by ligation and subsequent release of a suture around the coronary artery. This procedure did not induce thrombotic occlusion, which enabled us to reperfuse the ischemic myocardium without induction of ventricular fibrillation. Further, we described previously that platelets adhere to the intact carotid artery in the absence of morphological detectable vascular lesions. Thus it seems very unlikely that the herein described GPVI-dependent platelet-vessel wall interaction is mediated by exposed subendothelial collagen.
The mechanisms of platelet adhesion to the activated but intact endothelium have been shown to be mediated by various surface receptors on platelets and their respective ligands (5). On activated endothelium, which is found during I/R, but also in the early phases of atherosclerosis, various ligands on the luminal site of the endothelium become upregulated. Among others, vWF, P-selectin, fibronectin, and fibrinogen, but also Vn have been described (1, 10, 31, 36, 44) to be involved in these processes. During these interventions the endothelium remains intact and thus ligands originating from the subendothelial layers are unlikely to be binding partners for platelet receptors mediating platelet adhesion (31) . One study (55) , however, reports disruption of endothelial cells. However, the authors do not provide direct evidence for exposure of collagen under I/R. Recently, Vn was identified as a potential marker for endothelial activation during early atherosclerosis (43) . Thus Vn seems a plausible candidate as a binding partner on activated endothelium. Moreover, Vn is also incorporated into platelet clots during arterial thrombosis and therefore contributes to both platelet adhesion and aggregation (58) .
Although initially recognized as a collagen receptor (13), we identified novel ligands for GPVI including Vn. Interaction of GPVI with these proteins fundamentally deepen our understanding of how platelets adhere to activated endothelium. The fact that short-term administration of soluble GPVI-Fc reduces size of myocardial infarction suggests that administration of GPVI-Fc may be a promising strategy to prevent and treat platelet-mediated tissue injury such as myocardial infarction.
Activated platelets release proinflammatory mediators (e.g., TGF-␤1), and platelet adhesion mediated via GPVI contributes to myocardial inflammation (35) . A recent study (37) shows that platelet TGF-␤1 contributes to cardiac fibrosis and systolic dysfunction. In the present study, we show that GPVI-Fc reduces GPVI-mediated platelet degranulation of TGF-␤1 in vitro and systemic administration of GPVI-Fc attenuates expression of TGF-␤1 in the infarcted myocardium. Thus GPVIFc, which has been already evaluated in a clinical phase I study (56), may offer a novel therapeutic strategy to limit inflammation and to preserve myocardial function in the setting of myocardial infarction.
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